Thrombospondin in Tumor Microenvironment

被引:18
作者
Ramchandani, Divya [1 ]
Mittal, Vivek [1 ]
机构
[1] Weill Cornell Med, Dept Cardiothorac Surg, New York, NY 10065 USA
来源
TUMOR MICROENVIRONMENT: EXTRACELLULAR MATRIX COMPONENTS - PT B | 2020年 / 1272卷
关键词
Thrombospondin; Cancer; Microenvironment; CD36; CD47; Angiogenesis; TGF-beta; Adhesion; Spreading; Invasion; Migration; Dormancy; Pre-metastatic niche; Metastasis; Immune system; CELL-BINDING DOMAIN; INTEGRIN-ASSOCIATED PROTEIN; GROWTH-FACTOR BETA-1; NITRIC-OXIDE; TYPE-1; REPEAT; PLASMINOGEN-ACTIVATOR; HEPARIN-BINDING; UP-REGULATION; IN-VITRO; MACROPHAGE RECRUITMENT;
D O I
10.1007/978-3-030-48457-6_8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Thrombospondins (TSPs) are multifaceted proteins that contribute to physiologic as well as pathologic conditions. Due to their multiple receptor-binding domains, TSPs display both oncogenic and tumor-suppressive qualities and are thus essential components of the extracellular matrix. Known for their antiangiogenic capacity, TSPs are an important component of the tumor microenvironment. The N- and C-terminal domains of TSP are, respectively, involved in cell adhesion and spreading, an important feature of wound healing as well as cancer cell migration. Previously known for the activation of TGF-beta to promote tumor growth and inflammation, TSP-1 has recently been found to be transcriptionally induced by TGF-beta, implying the presence of a possible feedback loop. TSP-1 is an endogenous inhibitor of T cells and also mediates its immunosuppressive effects via induction of Tregs. Given the diverse roles of TSPs in the tumor microenvironment, many therapeutic strategies have utilized TSP-mimetic peptides or antibody blockade as anti-metastatic approaches. This chapter discusses the diverse structural domains, functional implications, and anti-metastatic therapies in the context of the role of TSP in the tumor microenvironment.
引用
收藏
页码:133 / 147
页数:15
相关论文
共 157 条
[1]  
Adams JC, 2000, DEV DYNAM, V218, P280
[2]  
Adams JC, 2011, CSH PERSPECT BIOL, V3, DOI [10.1101/cshperspect.a009712, 10.1016/j.biocel.2004.01.004]
[3]   The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice [J].
Agah, A ;
Kyriakides, TR ;
Lawler, J ;
Bornstein, P .
AMERICAN JOURNAL OF PATHOLOGY, 2002, 161 (03) :831-839
[4]   Emerging Topics on Disseminated Cancer Cell Dormancy and the Paradigm of Metastasis [J].
Aguirre-Ghiso, Julio A. ;
Sosa, Maria Soledad .
ANNUAL REVIEW OF CANCER BIOLOGY, VOL 2, 2018, 2 :377-393
[5]   Thrombospondin-1 and transforming growth factor-beta1 promote breast tumor cell invasion through upregulation of the plasminogen/plasmin system [J].
Albo, D ;
Berger, DH ;
Wang, TN ;
Hu, XL ;
Rothman, V ;
Tuszynski, GP .
SURGERY, 1997, 122 (02) :493-499
[6]   Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor [J].
Albo, D ;
Rothman, VL ;
Roberts, DD ;
Tuszynski, GP .
BRITISH JOURNAL OF CANCER, 2000, 83 (03) :298-306
[7]   Up-regulation of matrix metalloproteinase 9 by thrombospondin 1 in gastric cancer [J].
Albo, D ;
Shinohara, T ;
Tuszynski, GP .
JOURNAL OF SURGICAL RESEARCH, 2002, 108 (01) :51-60
[8]   Thrombospondin-1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer [J].
Albo, D ;
Berger, DH ;
Vogel, J ;
Tuszynski, GP .
JOURNAL OF GASTROINTESTINAL SURGERY, 1999, 3 (04) :411-417
[9]   CD47 ligation selectively downregulates human interleukin 12 production [J].
Armant, M ;
Avice, MN ;
Hermann, P ;
Rubio, M ;
Kiniwa, M ;
Delespesse, G ;
Sarfati, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (08) :1175-1181
[10]  
ARNOLETTI JP, 1995, CANCER, V76, P998, DOI 10.1002/1097-0142(19950915)76:6<998::AID-CNCR2820760613>3.0.CO